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Abstract
Many patients treated for a long time with opioids develop hypogonadotrophic hypogonadism with defi-
ciencies in dehydroepiandrosterone sulphate (DHEA-S) and testosterone. It is thought that hypogonadism
results in the symptoms of fatigue, depressed mood, slower cognition, increased pain sensitivity, amenorhoea
and loss of libido. It is debatable but quite possible that hypogonadism may also be one of the reasons of
opioid tolerance. Substitution of the hormones; testosterone and/or DHEA may potentially break this vicious
cycle, restore pain sensitivity to opioids and improve other symptoms improving patient's quality of life. In
this article we describe four patients with intractable pain treated compassionately with either DHEA or
testosterone. From the observations done by us, it is clear that substitution of those hormones has potentially
a profound effect on opioid activity, both aimed and adverse effects. Suggestions for future studies are
made.
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Introduction
Opioids are the mainstay of pain control in can-
cer [1] and are increasingly used among non-cancer
patients with chronic pain [2]. One of the dreaded
effects of is loss of pain sensitivity to opioids which
is defined as opioid tolerance and opioid induced
hyperalgesia [3, 4]. As the patients treated for their
pain are nowadays living longer, these phenomena
is gaining more importance in pain medicine. One,
but certainly not the sole component of opioid tol-
erance is development of hypogonadism which de-
creases pain sensitivity to opioids [5–8]. Among
opioids only buprenorphine has probably less in-
hibitory effects on synthesis of sex hormones [9].
Opioid-induced hypogonadism is a clinical con-
dition characterized by a low serum testosterone
and DHEA-S with clinical signs, including decreased
sexual desire, amenorrhoea, decreased pain thresh-
old, decreased energy, fatigue, depressed mood,
slowed cognition, impaired muscle mass and
strength, and diminished bone density [10].
Opioid-induced hypogonadism was first noticed
in the 1970's in patients on high dose methadone
for treatment of opioid dependence [11–13]. Stu-
dies among these patients showed depressed plas-
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ma testosterone, decreased sexual drive and de-
creased libido. It is possible that opioid induced
hypogonadism may affect many people worldwide
but until now remains unrecognized and untreat-
ed. The epidemiology of this phenomenon remains
unknown.
Clinical evidence
Abs et al. [8] showed that 25 out of 29 men on
long term intrathecal opioids had a serum testoste-
rone level < 9 nmol/L and a decreased libido. In the
same study all pre-menopausal women developed
amenorrhoea or dysmenorrhoea, and had a low se-
rum LH, estradiol and progesterone. Eighteen out
of 23 postmenopausal women were found to have
a decreased serum LH and FSH. Opioids caused also
central hypocorticism (in 15%), and GH deficiency
(in 15%). However, the DHEA-S was not measured
in this study.
A study of 54 men consuming oral opioids for
non malignant pain showed that 48 (89%) men
had subnormal levels of either testosterone or es-
trogen. This decrease in hormone level, was also
related to the quality of opioid consumed, dosage
and dosage form. Thirty nine men out of 45 (87%)
on opioids, reported normal erectile function be-
fore opioid use, then complained of erectile dys-
function or diminished libido once commenced on
opioids [14]. In the same study 47 women aged
between 30 to 75 years, who were receiving oral or
transdermal opioids (fentanyl) for the management
of nonmalignant pain were assessed. These were
compared to a control group of 68 women, not
receiving opioid analgesia. It was found that the
testosterone, oestradiol, and DHEA-S levels were
48% to 57% lower in the opioid using women. Also
LH and FSH levels were around 30% lower in pre-
menopausal and 70% lower in postmenopausal
opioid users. These women also reported a change
in menstruation cycle and often its cessation.
Oophorectomised women had a decrease of tes-
tosterone by 39%. These women were not taking
estrogen supplements, indicating that there is an
impairment of adrenal androgen production [14].
Mechanism of hypogonadism
The mechanism by which opioids depress tes-
tosterone levels, is primarily thought to be through
depression of pituitary function; decrease of gona-
dotrophins and decrease of hormone synthesis by
the adrenals and gonads [15]. This condition is
called hypogonadotrophic hypogonadism. Addi-
tionally to a decrease in gonadotrophins there is
also a decrease of ACTH [16] and increase of pro-
lactin [17–19].
In chronic opioid use, there is inhibition of beta
endorphins which may be responsible for an in-
creased sensitivity to pain. Increased need of (exo-
genous) opioids may be another mechanism of
opioid tolerance.
LH is normally secreted from the anterior pitu-
itary gland in response to gonadotrophic releasing
hormone (GnRH) from the hypothalamus. The LH
acts on Leydig cells in the testes to increase test-
osterone synthesis and secretion. Along with other
androgens, including DHEA-S and androstenedione.
It is thought that LH secretion is also regulated by
endogenous opioids, therefore in chronic opioid use,
there is a tonic inhibitory effect causing suppres-
sion of androgen production [20].
Testosterone comes in the form of transdermal
patches, oral tablets, gel and intramuscular injec-
tions. DHEA is available over the counter as a weak
androgen and it comes in tablets of 10, 25 and 50
mg. Each method of administration has its own risks.
In general the side effects of testosterone and DHEA
are related to the male hormone activity. In women
it can cause greasiness of the skin, unwanted hair
growth and acne, these are usually avoidable in low
doses. In men it can cause testicular atrophy, inferti-
lity and gynaecomastia, which are usually reversible
with cessation of treatment. There are controversial
views on whether  testosterone substitution may
cause prostate cancer (for review see: [10]) Substitu-
tion of testosterone and DHEA may have their
effects in younger man but may be ineffective or
even toxic in older patients [21, 22].
Polycythaemia is a risk apparent with any me-
thod of administration as testosterone stimulates
erythropoesis [22, 23]. Often this has a beneficial
effect due to raising the haemoglobin level, how-
ever it can precipitate cardiac or cerebrovascular
events if there is underlying disease. Lastly hepato-
toxicity may occur when using the oral tablets of
testosterone [24].
It appears that administration of exogenous
DHEA and/or testosterone seems to correct the symp-
toms of hypogonadism. However, it is unknown
whether abolishing hypogonadism also increases
pain sensitivity to opioids. Sex steroid synthesis is
very much increased in the spinal cord in some pain
conditions [25, 26].
Many studies have shown that men and women
differ in their pain response, both in animals and
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humans. Women have a lower pain threshold than
men [27–29] and this is thought to be due to the
levels of testosterone.
Recently we have measured sex steroids in sev-
eral patients with intractable malignant pain treat-
ed with opioids. In some patients with obvious
symptoms of hypogonadism we decided to com-
passionately administer either testosterone (in man)
or DHEA (in women). Here we describe responses of
several patients to androgens.
Case 1
A 66-year-old male was diagnosed eight year
ago with an ependymoma of the spinal cord. The
neurosurgical procedure resulted in a permanent
spinal cord lesion and paraplegia. His main prob-
lem is a constant pain in the rectum and legs, which
is not well controlled by medication. He was treat-
ed with increasing doses of fentanyl (up to 350
mg/hour), oral morphine up for breakthrough pain
(up to 1000 mg per day), ketamine, and gabapen-
tin. However, this medication was at times insuffi-
cient.
His testosterone level measured 4.6 nmol/L (nor-
mal 7–25) He was prescribed testosterone tablets
40 mg tds. This dose was later reduced to 40 mg
bd.
His pain response was remarkable. From alter-
nating “good and bad days” he has now “all aver-
age days with some pain but certainly of lower
intensity”. The need of the oral morphine break-
through doses have decreased to occasional 120
mg a day. He also feels brighter in himself, and
more cheerful. Due to his concerns about potential
hepatotoxicity of testosterone tablets he was
swapped to the testosterone patches 5 mg/24 hr
after one month. He felt that the effect of the
patches was less strong but when the dose of
patches was doubled he felt dizzy and nauseated.
He also had a skin reaction to the patch and the
patches were discontinued. He than tried testoste-
rone gel 5 g per day on the skin. He got certainly
a benefit from the gel, as “if he forgets to apply it,
he gets pain later in the day”. As the control test-
osterone level remained low (3.5 nmol/L) the dose
was increased to 10 g testosterone gel a day. Three
weeks after this dose escalation he became un-
arousable and his breathing was slow. He was ad-
mitted to the hospital where the dose of fentanyl
was reduced to 300 mg/hour and the testosterone
was discontinued. He apparently has much less
pain now.
Case 2
A 50-year-old man, diagnosed with non small
cell carcinoma of the lung was subjected to lobec-
tomy and chemotherapy. On thoracotomy the tu-
mour appeared to infiltrate the pleura. Immediately
after the operation he suffered of severe post-tho-
racotomy pain and this pain remained intractable
for 8 months. Oral morphine combined with trans-
dermal fentanyl with multiple co-analgesics ap-
peared to be ineffective. He also tried for a short
time diamorphine 20 mg/24 hours in a continuous
sc infusion, which put him asleep but relieved his
pain only partially. After 8 months he was diag-
nosed with the tumour recurrence and started on
erlotinib (Tarceva). As the pain continued to be
a problem plasma testosterone was determined and
was 1.2 nmol/L. (normal 7–25 nmol/L). Prior to start-
ing with testosterone supplements his medication
was as follows: buprenorphine patch 55 mg/hr, pre-
gabalin 100 mg bd, MST 60 mg bd, paracetamol
1500 mg, sevredol 50 mg PRN and dexamethasone
1 mg od. He was started on testosterone patches 5
mg/24 hours and his pain decreased rapidly within
one day. He remained pain free despite CT scan
showing no changes to the tumour volume as the
result of treatment. Gradually the testosterone se-
rum level has increased over 4 months to 4.8 nmol/L,
5.9 nmol/L and most recently 6.6 nmol/L.
As he continued to be pain free, he gradually
reduced his medications. At that moment his medi-
cation was as follows buprenorphine patch 10 mg/
/hr, pregabalin 50 mg bd, paracetamol 1 g prn, dexa-
methasone 1 mg od and erlotinib (Tarceva) 150 mg
od. He did not experience any significant adverse
effects to testosterone. Now four months later he
reports still to be pain free and to have increased
sense of well being, more energy and being less de-
pressed but he has not observed any increase in libi-
do yet. After maximal reduction of the analgesic dose
we plan to discontinue testosterone.
Case 3
A 54-year-old man with multiple myeloma was
suffering severe pain in his bones, muscles and joints.
The history of pain preceded the diagnosis by seve-
ral months. The pain was never well controlled with
oral analgesics and the only period of time he can
recall of being pain free was after the autologous
bone marrow transplantation. However, this pain-
free period lasted only for several months. The joints
and bone pain reoccurred in the absence of a my-
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eloma recurrence in the bone marrow. The pain was
severe, generalized, worse on movement and with
deep inhalation. The pain was partially relieved with
combination of methadone 40 mg bd, amitriptyline
100 mg bd and prednisolone 40 mg. He could not
tolerate higher doses of methadone as he was com-
plaining of increased breathlessness. He reported that
his nipples were swollen and sensitive to touch, but
there was no discharge. The plasma testosterone was
3.9 nmol/L (normal 7–25 nmol/L), FSH 1.5 U/L (nor-
mal 2–9 U/L) and LH 3.9 U/L (normal 2–7 U/L). He
was prescribed by the haematologist, an intramus-
cular depo testosterone injection of 250 mg, with
the aim to repeat in 4 weeks. Within several days
after injection he described his feeling as “terrible”
and “getting worse each day”. The pain intensity
increased, he was achy everywhere and short of
breath. He was admitted to ICU eight days after
injection, due to breathlessness, haemoptysis and
worsening renal function (his basic plasma creati-
nine was 163 mmol/L but increased after testoster-
one injection to 265 mmol/L). The methadone dose
was reduced to 5 mg bd and he was discharged
home several days later. Eight weeks after the injec-
tion of depo-testosterone his plasma testosterone
was still 9 nmol/L. He had substantially less pain
than before and moved with more ease despite con-
tinuing on methadone 5 mg bd.
Case 4
A 29-year-old woman was diagnosed with an
adenocarcinoma of the uterus and bony metasta-
sis, for which she had a radical hysterectomy with
left salpingo-oophorectomy and 12 cycles of che-
motherapy and radiotherapy.
Her symptoms were fairly well controlled until
she presented with right sided pain, which was un-
responsive to fentanyl patches up to 200 mcg/hr
and unresponsive to increasing doses of oral mor-
phine up to 1400 mg per day. The pain localised in
the right lumbar area and radiated down the back
and side of her leg to her knee, made worse by
movement. This pain was found to be due to im-
pingement/irritation of the superior cluneal nerve,
lateral cutaneous branch of the iliohypogastric nerve
and lateral cutaneous branch of the XII subcostal
nerve. She was treated with bupivacaine and De-
poMedrone injections, which eased the pain within
20 minutes. She was then able to decrease her daily
use of oral morphine to 240 mg, which at this time
was enough to control all her other pain. After a
while the pain in the left hip emerged and could
not be controlled by the increased doses of the opi-
oids. Bone metastases and femoral fracture which
caused this pain were treated with intra medullar
nail and radiotherapy. Despite this treatment her
oral opioid doses were increased again to 1200 mg
per day, with only minor effect. She was admitted
to the Hospice for pain control, her medications for
pain at this time were fentanyl 250 mg/hr, oral mor-
phine sulphate up to 1000 mg a day, dexametha-
sone 6 mg od, amitriptiline 25 mg od, naproxen
500 mg bd and hyoscine butylbromide 60 mg
a day. It was noticed that even with such a high
dose of opioids she was never constipated. She was
swapped gradually from fentanyl to buprenorphine
70 mg/hour but she was still wearing a small fenta-
nyl patch of 25 mg/hour. With this medication she
was much better pain controlled for two months
and was able occasionally to go home to see her
children. She then began suffering with severe left
hip pain again so the buprenorphine dose was in-
creased to 140 mg/hr. At that moment her DHEA-S
levels were below detection limit of  0.4 mmol/L
(normal 1.8–10.3 µmol/L) and testosterone 0.76
nmol/L (normal 0–4.1 nmol/L). She was commenced
on oral DHEA 50 mg od. Over night she experienced
a benefit of being free from pain and therefore felt
more rested in the morning. Also for the first time,
she became constipated and needed laxatives. Over
the next couple of days she continued to be pain
free and in better spirits. However she deteriorated
rapidly and passed away after being two days in
coma.
Discussion
Determination of sex steroids in patients with
intractable cancer pain may reveal hypogonadism.
This confirms previous observations in patients with
cancers and non-malignant conditions treated with
high dose of opioids [5, 8, 30].
Administration of testosterone or DHEA result-
ed in all patients in a rapid decrease of pain intensi-
ty. However in several patients, treated with high
doses of opioids administration of testosterone
greatly increased their toxicity necessitating two
patients to be admitted to the intensive care. In
both these patients the dose of opioids was re-
duced and testosterone was discontinued. This re-
sulted in long standing improvement of pain sug-
gesting that high dose of opioids was the reason
for opioid induced hyperalgesia and concomitant
depression of plasma testosterone and/or DHEA-S
levels.
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In one patient testosterone treatment resulted
in rapid and complete disappearance of longstand-
ing intractable pain symptoms of post thoracoto-
my pain. This happened despite unchanged com-
puted tomography findings which makes improba-
ble that the observed effect was due to immuno-
chemotherapy. It could be possible that longs stand-
ing effects on the sex hormone levels was also due
to the swap to transdermal buprenorphine. Bu-
prenorphine had been reported not to compromise
testosterone levels [9, 31].
Administration of DHEA to a young woman on
high dose of opioids was not associated with in-
creased toxicity and resulted in better pain control.
A lot needs to be investigated in adequately de-
signed and powered clinical studies. It seems that
there is a strong relationship between the high dose
of opioids and hypogonadism. Sex hormones ad-
ministered to patients with intractable pain may
potentially be helpful. However, testosterone may
also greatly increase the opioid toxicity.
Therefore it is advisable, similarly to the treat-
ment advocated in opioid induced hyperalgesia [32]
first to reduce the opioid dose. Reduction of the
opioid dose by itself may relieve the hormonal sup-
pression and result in higher sex hormones levels.
So, substitution of testosterone and/or DHEA can
potentially be used only for a period of several weeks
or months, making the discussion of potential in-
duction of hormone-related cancers less relevant.
The preparations used for the purpose as de-
scribed above should be titrated from the low dose
and should be short acting so their effect can be
reversed when needed. The therapy should be mon-
itored by the frequent measurements of testoster-
one and DHEA-S blood levels.
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